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Cholera toxin (CT) stimulates the epidermal adenylate 
cyclase system in vitro. This stimulation was demon-
strated in the skin (slice) floating system and the homog-
enate (membrane) assay system. With the floating sys-
tem, the addition of CT to the incubation medium caused 
a marked accumulation of cAMP intracellularly, which 
was both dose- and time-dependent. A 1-h lag time was 
present before activation started. Pretreatment of the 
skin with CT changed the nature of the stimulatory effect 
caused by epinephrine and histamine, i.e., the transient 
accumulation of cAMP (a peak at 5 min and subsequent 
decrease) was no longer observed but the stimulation 
became persistent. 
With the membrane assay system in which the recep-
tor components had been uncoupled, adenylate cyclase 
activities were markedly stimulated by CT (with gua-
nosine-5'-triphosphate, GTP), guanylyl-,B,y-imidodiphos-
phate (GTP-analog, Gpp[NH]p), or sodium fluoride. The 
stimulation was both dose- and time-dependent without 
an initial time lag. Either CT or Gpp[NH]p could fully 
activate adenylate cyclase, and the simultaneous addi-
tion of both did not cause further additive stimulation. 
These data are consistent with the view that the GTP-
regulatory protein plays a key role in the activation of 
adenylate cyclase, and that CT both activates the cata-
lytic unit and modifies the response to receptor hor-
mones through its action on this protein. 
The adenylate cyclase system in the cell membrane is com-
posed of at least 3 components: a receptor site (R), a nucleotide 
regulatory protein (N), and a catalytic unit (C). Recent studies 
have shown that N has a pivotal role in the adenylate cyclase 
system [1-6] and the activity of N is regulated by the guanine 
nucleotide; i.e., N is active when guanosine-5'-triphosphate 
(GTP) is present and N is inactive when guanosine-5' -diphos-
phate (GDP) is attached. In the basal state GDP occupies N 
[7]. Hormones that activate adenylate cyclase act by enhancing 
replacement of the bound GDP by GTP [7], and subsequent 
hydrolysis of the bound GTP terminates the activation of 
adenylate cyclase [8]. 
Replacement of GTP by the hydrolysis-resistant analogue 
guanylyl-,B,y-imidodiphosphate (Gpp[NH]p) produces a per-
sistently active state [9]. Cholera toxin (CT) can activate ade-
nylate cyclase of intact cells and broken cells [10] by catalyzing 
the transfer of adenosine-5'-diphosphate (ADP)-ribose from 
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nicotinamide adenine dinucleotide (NAD) to a 42,000 M,. poly-
peptide which is part of N [11]. CT activation has been ex-
plained by either inhibiting GTP hydrolysis at N [12] or en-
hancing attachment of GTP instead of GDP in a manner similar 
to hormones [13,14] , or both. 
To date, we have reported epidermal adenylate cyclase sys-
tems coupled with various receptors, such as catecholamine 
[15], prostaglandin E [16], histamine [17], and adenosine [18]. 
These receptors individually stimulate their own adenylate 
cyclase systems in the epidermis in a specific manner [19], while 
CT is supposed to modify N in a nondiscriminatory way to 
activate all of the receptor systems at the same time. In an in 
vitro system, theN can be coupled with a foreign R (from other 
species) to mediate a hormone reaction [20]. The effects of CT 
on growth and differentiation of keratinocytes as well as those 
on the cyclic AMP levels in cultured epidermal cells have been 
reported [21-23]. In skin, CT presumably acts on the N com-
ponent of adenylate cyclase as it does in other tissues, however 
its obligatory role has not been documented. 
In our attempt to dissect each component of the epidermal 
adenylate cyclase systems, we now demonstrate that CT stim-
ulates the N component of epidermal adenylate cyclase both in 
an in vitro floating system and in an homogenate assay system. 
MATERIALS AND METHODS 
M a.teria.ls 
[2,8-3H]cAMP (sp act 36.4 Ci/mmol) was purchased from New 
England Nuclear (Boston, Massachusetts), [a-32P] adenosine-5'-tri-
phosphate (ATP) (sp act 30-50 Ci/nmol) from Amersham, U.K. , a 
cAMP radioimmunoassay kit from Collaborative Reseru·ch Inc. (Wal-
tham, Massachusetts), cholera toxin (whole, A and B unit) from Cal-
biochem (LaJolla, California), and alumina (Neutral Type WN-3) and 
Dowex 50W (50 X 4-400) from Sigma (St. Louis, Missouri). All other 
chemicals used were of the highest grade available. 
Floating Experiment 
Skin slices (approximately 80% epidermis) from domestic pigs were 
taken by a keratome with the cutting blade adjusted to 0.2 mm or 0.3 
mm. The skin slices were cut 5 X 5 mm squru·e at 4 °C and the skin 
squares were floated keratin layer up on Hanks' balanced salt solution. 
After preincubation at 37°C, the squru·es were incubated in various 
chemicals and drugs. In a case of long iilcubation, the squares were 
placed in a humidity- and temperature-controlled incubator having a 
95% air/5% C02 supply. After incubat ion they were frozen by dry ice to 
stop the reaction; the cAMP contents were measured by radioimmu-
noassay [24] with micromodification [25]. Protein was measured by the 
method of Lowry et a! with human albumin as a standard [26]. 
DTE: dithioerythreitol 
EGT A: ethyleneglycol-bis-(,8-aminoethyl ether)-N ,N' -tetraacetic 
acid 
GDP: guanosine-5' -diphosphate 
Gpp[NH]p: guanylyl-,8, y-imidodiphosphate 
GTP: guanosine-5' -triphosphate 
Hepes: N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic acid 
IBMX: isobutylmethylxanthine 
N: nucleotide regulatory protein 
NAD: nicotinamide adenine dinucleotide 
NaF: sodium fluoride 
R: receptor site 
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Membrane Assay System 
Pig epidermal cell membrane was prepared as follows. Fresh pig skin 
taken by a keratome with 0.3-mm thickness was finely minced with 
scissors and then homogenized by a glass-Teflon homogenizer (Potter-
Elvehjem) with 15-20 strokes in 50 mM Hepes buffer (pH 8.0) contain-
ing 0.1 mM EDTA and 1 mM MgC!,. The homogenate was filtered 
through double-layered gauze. The dermis, which could not be de-
stroyed by this homogenization, remained on the gauze [27]. The 
filtrate was centrifuged at 20,000 g for 20 min and the resulting precip-
itate (the membrane) was resuspended in the above buffer (4-5 mg 
protein/ rnl) . These procedures were repeated 3 times for washing. The 
membrane preparations were quickly frozen in acetone-dry ice and 
stored at -70°C until assayed. 
Adenylate Cyclase Assay 
Assays were performed in a fmal volume of 200 Jll. The reaction 
mixture contained 25 mM Hepes (pH 8.0) , 5 mM MgC!,, 0.04 mM EGTA, 
0.2 mM isobutylmethylxanthine (IBMX), 0.2 mM ATP, 1.5-2 f.'Ci/assay 
[a-32P]ATP, 0.2 mM cAMP, 1 mM phosphoenolpyruvate, and 20 JLg/rnl 
pyruvate kinase. When CT was added for the activation, NAD (1.25 
mM), dithioerythreitol (DTE) (1 mM), and GTP (200 JLM) were also 
added to the mixture. After incubation at 37°C, reaction was stopped 
by the addition of 200 f.'l of 2% sodium dodecyl sulfate and the mixture 
was immediately boiled for 3 min. Subsequently, 50 f.'l of CHJcAMP 
(30,000 cpm) and 500 JL! of 10 mM imidazole buffer (pH 6.8) were added 
and the entire mixture was passed through Dowex 50 and alumina 
columns consecutively to isolate [a-32P]cAMP [28]. [32P]cAMP recov-
eries from the consecutive columns were 60-80%. Each experiment was 
repeated to test reproducibility. However, due to considerable varia-
tions in adenylate cyclase activities in each membrane preparation, a 
representative figure rather than an average is shown. Variations within 
specific experiments are minimal as indicated in Tables I and II. 
RESULTS 
Results with an In Vitro Floating System 
The incubation of CT with the epidermal squares caused 
stimulation of pig epidermal adenylate cyclase in both a time-
and a dose-dependent manner (Fig 1). However, the CT stim-
ulation required prolonged incubation (over 1 h) and the effect 
persisted. Usually a 30-min incubation with CT (0.1-20 JLg/rnl) 
was not effective and a dose at 0.1 JLg/rnl or less resulted in 
little or no cAMP accumulation through a 6-h incubation. 
Because the cAMP level in the epidermis in this floating 
system is due to a balance of cAMP production (by adenylate 
cyclase) and degradation (by phosphodiesterase), the effect of 
a phosphodiesterase inhibitor (IBMX) addition was also ex-
amined. Fig 2 shows that the addition of IBMX (1 mM) mark-
edly potentiated the effect of CT, even at the CT concentration 
level of 0.1 JLg/rnl, which showed only little stimulation by itself 
after 4 h (Fig 1). These data suggest that a low dose of CT can 
activate adenylate cyclase in the epidermis and its effect is not 
through the inhibition of phosphodiesterase. Since inhibitors of 
RNA and protein synthesis potentiated the effect of CT in 
cultured cells [29], we have also added cycloheximide (1 JLg/rnl) 
to the CT stimulation medium. However no potentiation oc-
curred (data not shown). 
Fig 3 shows that a 2-h pretreatment of CT (1 JLg/rnl) changed 
the responses to epinephrine (5 X 10- 5 M) and histamine (5 X 
10- • M) stimulation. This pretreatment itself did not affect the 
cAMP level in the epidermis (Fig 1) and therefore any difference 
in hormone stimulations with and without CT pretreatment 
can be compared. After the CT pretreatment, the epinephrine 
or histamine stimulation caused faster and higher cAMP ac-
cumulation than did control (no treatment) and the cAMP 
levels did not decrease for at least 30 min (Fig 3A,B). The same 
results were found when the slices were incubated another 2 h 
in Hanks' balanced salt solution alone at 37°C following pre-
treatment with CT and washing (data not shown). This per-
sistent effect is consistent with the fact [10] that adenylate 
cyclase in the epidermis is irreversibly changed (or activated) 
by the CT pretreatment. 
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TABLE I. Combinations of various stimulators on the adenylate 
cyclase (N -C complex of membrane preparation) 
Addition 
None 
NaF (10 mM) 
NaF + Gpp[NH]p (100JLM) 
NaF + CT (150 JLg/rnl) 
NaF + GTP (100 JLM) 
Gpp[NH]p 
Gpp[NH]p + CT 
Gpp[NH]p + GTP 
CT 
GTP 
Adenyla te cyclase activity 
(pmol/mg protein/ 30 min) 
13 ± 1.1 
99 ± 0.8 
113 ± 2.5 
172 ± 3.0 
102 ± 3.0 
77 ± 0.7 
103 ± 1.2 
43 ± 0.2 
90 ± 1.8 
25 ± 0.8 
Details of assay condition are shown in Materials and Methods. CT 
stimulus contained GTP (100 JLM), NAD (1.25 mM), DTE (1 mM). 
Values shown represent the means± SE of triplicate determinations. 
TABLE II. Effects of cofactor of CT stimulation on NaF-stimulated 
adenylate cyclase activity 
Addition 
NaF (10 mM) 
NaF + DTE (1 mM) 
NaF + NAD (1.25 mM) 
NaF + DTE + NAD 
NaF + DTE + NAD + GTP (100 JLM) 
NaF + DTE + NAD + CT (100 JLg/ 
rnl) 
NaF + DTE + NAD + GTP + CT 
Adenylate cyclase 
activity 
(pmol/mg protein/30 min) 
89 ± 3.2 
100 ± 2.5 
174 ± 3.4 
169 ± 7.6 
150 ± 3.9 
145 ± 2.8 
151 ± 1.3 
Details of assay condition are shown in Materials and Methods. 
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FIG 1. Time course of the effect of CT on the cAMP levels in the 
skin slice floating system. Details of experimental conditions are de-
scribed in Materials and Methods. The concentrations of CT were: 
~ 20 Jlg/ ml, 6-6 5 Jlg/rnl, 0-0 1 Jlg/ml, ·-· 0.1 Jlg/ml, X-X 
control (no addition). Data are averages of 2 separate experiments in 
duplicate assay each. 
Results with a Membrane (Homogenate) Assay System 
Fig 4 shows the time course of cAMP accumulation with the 
homogenate assay system. Both CT and sodium fluoride (NaF) 
markedly stimulated epidermal adenylate cyclase. Although 
CT potentiated adenylate cyclase in both the floating system 
and the homogenate assay system, NaF did not activate the 
floating system (data not shown) . The stimulatory effects of CT 
and NaF were also tested with varying amounts of epidermal 
membrane (Fig 5). Thus we chose incubation times of 30 min 
or 45 min with 200- 300 JLg of membrane for subsequent exper-
Aug.1983 CHOLERA TOXIN STIMULATION OF EPIDERMAL ADENYLATE CYCLASE 133 
30 
c 
'Ci) 
....... 20 0 I-
a... 
0') 
E 
-..... 
0 
0 D~ ~==• 'I 
E 10 
a... 
0 5 hours 
FIG 2. Effects of IBMX (1 mM) addition to the in vitro floating 
system: A-A control, !::.-!::. control + IBMX, •-• 0.1 1-1g/ ml CT, 
0-0 0.1 1-1g/ml CT + IBMX, ·- 1!-'g/ ml CT, D-O 1!-'g/ ml CT + 
IBMX. Data are averages of 3 different skin slices in duplicate assay 
each. 
20 
10 
c: 
·a; 
..... 
0 
.... 
c.. 
Ol 
E 0 
-0 20 E 
CL 
10 
• 
0 30 min 
FIG 3. Effect of CT pretreatment. Skin slices were preincubated in 
Hanks' media for 2 hat 37"C with CT (1!-'g/ ml) (0-0) or without CT 
(._e). Subsequently, (A) epinephrine (5 x 10-s M) was directly added 
to the media; (B) histamine (5 X 10- 4 M) was directly added to the 
media. 
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FIG 4. Time courses of the effects of NaF, CT, and control activity 
on the N-C complex of the adenylate cyclase system with epidermal 
membrane preparation. Details of assay conditions are described in 
Materials and Methods. The concentration of stimulators are 0-0 
NaF 10 mM, !::.-!::. CT 10 ~/ml, X-X control (no addition). In each 
assay 300 1-'g membrane was used. Values shown represent duplicate 
determinations. 
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FIG 5. Effects of CT, GTP analog, and NaF with varying amounts 
of epidermal membrane preparation. The concentration of stimulators 
are 0-0 NaF 10 mM, 0-0 Gpp(NH]p 10 /LM, !::.-!::. CT 10 1-1g/ ml . 
Data are expressed as pmol cAMP formed/30 min. Values shown 
represent duplicate determinations. 
iments. Fig 5 also shows marked stimulation by an analog of 
GTP (Gpp[NH]p). 
The CT activation of adenylate cyclase requires GTP in a 
dose-dependent manner (Fig 6A). Whole CT and "A" subunit 
(active unit of CT) had the same dependency on GTP concen-
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FIG 6. Effect of GTP and its analog on the membrane preparation. 
A, The effect of GTP on CT-stimulated adenylate cyclase. The concen-
trations of CT used were whole toxin 15 JLg/ml (e-e) and "A" subunit 
50 JLg/ml (0-0). The basal activities without CT or GTP, and those 
with CT but without GTP ranged from 22-29 pmol/mg protein/30 min. 
Abscissa shows different GTP concentrations in a log scale. DTE 
(1 m M) was omitted when the "A" subunit of CT was used. B, The 
effect of Gpp[NH]p or GTP alone without CT on the membrane 
adenylate cyclase preparation. Abscissa indicates concentrations of 
GTP (0 - 0 ) or the analog Gpp[NH]p (e----e) in a log scale. No CT 
was added. The basal control value without guanine nucleotides was 
24.5 pmol/mg protein/30 min. In both A and B, the ordinate indicates 
adenylate cyclase activity as described in Materials and Methods. 
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FIG 7. Effect of CT on the membrane preparation. The CT used 
was whole toxin (e-e) or "A" subunit (0 - 0 ). Other additions to the 
reaction mixture were GTP (100 JLM) , NAD (1.25 mM), and DTE (1 
mM). In the case of cholera toxin "A" subunit activation, DTE was 
omitted. The average adenylate cyclase activity without both CT and 
exogenous GTP and that without CT but with GTP were about 20 and 
33 pmol/mg protein/30 min, respectively. The inset shows gross 
(macro) concentration effects of CT which was a separate experiment. 
Each value represents an average of duplicate determinations. 
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FIG 8. Effect of NAD on the adenylate cyclase stimulators. The 
abscissa indicates the different concentrations of N AD (M) in a log 
scale and the ordinate indicates adenylate cyclase activity. The concen-
tration of stimulators was NaF (.6.-.6.) 10 mM and Gpp[NH]p (0-0) 
100 JLM, and adenylate cyclase activities at 0 NAD concentration were 
58 and 48 pmol/mg protein/30 min, respectively. Basal control activities 
(without CT, NaF, or Gpp[NH]p but with different concentrations of 
NAD as indicated) are shown as 0-0. Each value represents an 
average of triplicate determinations . 
tration. The stimulatory effect by GTP alone (without CT) was 
minimal, while that by the analog alone was clearly dose-
dependent (Fig 6B). The CT stimulation of adenylate cyclase 
(with 200 p.M GTP) was also dose-dependent (Fig 7), but 1 p.g/ 
ml CT was not effective in this system. The CT stimulation 
with the homogenate assay system appears to be less sensitive 
than that with the in vitro floating system (cf. Fig 2). 
Table I shows the result of combinations of various stimula-
tors such as NaF (10 mM) , Gpp[NH]p (100 p.M) , CT (150 p.g/ 
ml), and GTP (100 p.M) on adenylate cyclase with the membrane 
assay system. The concentrations of stimulators were used at 
maximum stimulatory doses to examine possible additive ef-
fects. With this homogenate ·assay system, one cannot demon-
strate a hormone effect (receptor site), and all stimulators in 
Table I act through the nucleotide binding protein(s) (N) and 
not through t he receptor site (R) . Table I shows that the 
combinations ofNaF and guanine nucleotide (GTP or Gpp[NH] 
p) were not additive: the fact suggests that both act on N with 
a common adenylate cyclase (C). The effect of Gpp[NH]p was 
inhibited by GTP, suggesting that Gpp[NH]p and GTP bind to 
the same site on N . 
Table I shows that the combination of N aF and CT gives an 
additive stimulation. For the CT stimulation with the homog-
enate assay system, we always added 3 cofactors such as GTP, 
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NAD, and DTE. Therefore, we further examined whether or 
not one of the cofactors might have enhanced NaF stimulation 
(Table II) . It is obvious that NAD (1.25 rnM) strongly enhanced 
the NaF stimulation. As shown in Fig 8, only the NaF stimu-
lation is enhanced by NAD at rather high concentrations. The 
basal adenylate cyclase- and Gpp[NH]p-stimulated activities 
were not affected at all. 
DISCUSSION 
Although the N protein was suggested as a component of the 
adenylate cyclase system 10 years ago [30], its significance was 
unknown until recently [1,2,5,6,10]. One typical example that 
exemplifies the obligatory role of N is the fmding that in 
mutants of S49lymphoma cells lacking this N, hormonal stim-
ulation did not activate adenylate cyclase and the addition ofN 
(from another strain) restored the hormonal effect, resulting in 
cAMP accumulation [6]. In the present study we have demon-
strated unequivocally the presence of N in epidermal adenylate 
cyclase systems. Our experiments with the membrane fraction 
showed direct actions of GTP analog and of CT (plus GTP) 
with the N-C complex. With the epidermal slice system we 
found that modifications of N via CT altered the hormonal 
responses of epidermal adenylate cyclase. 
With the floating (intact cell) system, the CT stimulation of 
adenylate cyclase required exposure for more than 1 h, while 
the stimulation was immediate with the membrane (broken 
cell) system. CT is composed of "A" and "B" subunits; the "A" 
subunit penetrates further into the cell membrane [31] while 
the "B" subunits remain on the cell surface and are bound to 
the putative CT receptor. The initial time lag with our floating 
system is probably due to the time required for "A" subunit 
separation, penetration, and subsequent activation of N . Thus 
far we can count only a few epidermal surface receptors such as 
those related to adenylate cyclase systems [15-18) and epider-
mal growth factor receptors [32]. Perhaps now we can add this 
CT receptor to the above list as one of the cell surface receptors 
of skin. 
A peculiar finding in the CT action with pig epidermis is the 
lesser sensitivity of the membrane system as compared with 
that of the floating system. Generally, in other tissues the 
membrane system is so sensitive that only nanogram quantities 
of CT are required for activation. This insensitivity may be due 
to a deficiency of another cofactor called "cytosol factor" for 
CT activation [10,33]. Because ofthis possibility, we have added 
skin extract, which was separated by Sephadex G 150, to the 
assay mixture. The addition did not increase the sensitivity of 
the membrane system, so an explanation for the insensitivity is 
still lacking. 
The activation of purified GTP-regulatory protein by fluoride 
ion requires the presence of magnesium ion and ATP [34]. 
Sternweis and Gilman [35] just recently reported that an alu-
minum contamination of ATP but not ATP itself is the actual 
factor for the activation. Significant amounts of ::Jurninum ion 
were also found in other commercial nucleotides such as ADP 
and GTP. Our unexpected finding that the combination ofNaF 
and NAD activates maximally adenylate cyclase activities may 
be explained by this newly discovered aluminum effect. The 
data that the activation was evident only at high NAD concen-
tration (Fig 8) suggest that the effective component is a contam-
inant such as aluminum rather than NAD itself. Aluminum ion 
does not appear to activate theN protein in the absence of NaF 
[35]. This is also consistent with qur observation that the high 
concentration of NAD itself did not enhance the stimulation by 
the GTP analog (Fig 8). 
The membrane preparation in our study was best prepared 
using a glass-Teflon homogenizer for a short period. Under this 
condition, the N-C complex is well preserved. Use of a glass-
glass homogenizer, even under mild conditions, led to a loss of 
the complex. Our crude membrane preparation also contains 
the R unit since we can measure the .8-adrenergic receptor with 
a radiolabeled antagonist (unpublished observation). Despite 
the fact that the membrane preparation contains all 3 basic 
components for the hormone action (R, N, and C), epinephrine 
no longer causes cAMP accumulation once the epidermal cell 
has been mechanically destroyed. The data suggest that for the 
coupling of the entire adenylate cyclase system, certain struc-
tural (mechanical) supports and/or other cofactor(s) may be 
needed. In order to keep the hormone responsiveness, we are 
now developing a new assay system with epidermal cells that 
are prepared by trypsinization followed by osmotic shock. Stud-
ies with such "leaky cells," in which all 3 components are still 
coupled and yet phosphorylated cofactors can be incorporated, 
are currently under way. 
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Epidermal Pyridoxal 5'-Phosphate Depletion, Inhibition of DNA 
Synthesis, and Inhibition of the Expression of Ornithine Decarboxylase 
Activity by the Vitamin B-6 Antagonist 4'-Deoxypyridoxine 
MICHAEL J. CONNOR, PH.D. AND NICHOLAS J. LOWE, M.D., M.R.C.P. 
Division of Dermatology, UCLA School of Medicine, Los Angeles, California, U.S.A. 
The induction of ornithine decarboxylase (ODC) activ-
ity may be an essential component of skin tumor pro-
motion. ODC requires pyridoxal5'-phosphate (PLP) as a 
cofactor. We have measured the epidermal PLP concen-
tration and investigated its relationship to DNA synthe-
sis and ODC activity in the hairless mouse. 
The epidermal PLP concentration was approximately 
1.0 11-g/ g. When tape-stripping was used to induce ODC 
activity in the epidermis the concentration of PLP was 
significantly elevated 4.5 h later at the time of peak ODC 
activity and when DNA synthesis was reduced. 
Systemic treatment with the vitamin B-6 antagonist 
4'-deoxypyridoxine (4~DOP) significantly reduced the ep-
idermal PLP concentration and DNA synthesis. The ODC 
activity induced in the epidermis 4.5 h after tape-strip-
ping in 4-DOP-treated mice was only 17% of that induced 
in untreated tape-stripped controls. In in vitro experi-
ments it was shown that while 4-DOP does not inhibit 
ODC activity, a major metabolite of 4-DOP, 4-DOP-phos-
phate (K; .06 mM), does. In mixing experiments it was 
shown that the epidermal extracts from 4-DOP-treated 
mice did not contain significant amounts of ODC inhibi-
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Abbreviations: 
4-DOP: 4'-deoxypyridoxine 
4-DOP-phosphate: 4'-deoxypyridoxine-phosphate 
ODC: ornithine decarboxylase (EC 4.1.1.17, L-ornithine carboxyl-
ase) 
PLP: pyridoxal 5' -phosphate 
tors. 4-DOP may inhibit ODC induction in the epidermis 
by depleting the PLP content. 
The pyridoxine (vitamin B-6) derivative, pyridoxal 5' -phos-
phate (PLP), is a cofactor for several mammalian decarboxy-
lases including the polyamine synthesis enzyme ornithine de-
carboxylase (ODC). ODC activity is induced in mouse skin by 
tumor promoters [1] and polyamine levels are elevated in 
proliferating . tissues (2]. Current evidence indicates that the 
induction of ODC activity, while not necessarily specific for 
tumor promotion, may be an essential component of the process 
(3-5]. If the induction of ODC activity is essential for carcino-
genesis, then inhibitors of ODC should be good candidates as 
antitumor agents. In this respect the irreversible, highly specific 
(suicide) inhibitor of ODC, alpha-difluoromethyl-ornithine, has 
recently been shown to inhibit tumor promotion in mouse skin 
[5,6]. 
Hepatocarcinogenesis is reduced [7,8] and the growth of 
hepatomas severely impaired [9] in pyridoxine deficiency. The 
pyridoxine antagonist 4'-deoxypyridoxine (4-DOP) irihibits tu-
mor growth [10] and has been used in the treatment of adult 
lymphatic leukelnia [11]. Tissue putrescine and spermidine 
levels are reduced in pyridoxine deficiency [12], and the PLP 
concentration may therefore regulate putrescine synthesis. 
Murray and Froscio [13] found that reduced levels of ODC 
activity were induced in the epiderlnis of pyridoxine-deficient 
compared to pyridoxine-replete Inice after treatment with the 
tumor promoter tetradecanoylphorbol-13-acetate. Thus epider-
mal ODC activity is influenced in vivo by the pyridoxine status 
and this may explain in part the anticancer and antiproliferative 
properties of pyridoxine deficiency. 
We have been investigating the possible use of 4-DOP for 
regulating the supply of PLP to the epidermis to control ODC 
activity more directly, and to establish a new route for inhibiting 
